Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Terns Pharmaceuticals Inc.
TERN | US
44.24
USD-2.54
-5.43%
TERN | US
Loading StockChartView...
About Terns Pharmaceuticals Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
12/03/2026
Close
44.24
Open
45.37
High
45.37
Low
43.64
Terns Pharmaceuticals Inc. a clinical-stage biopharmaceutical company develops small-molecule single-agent and combination therapy candidates for the treatment of oncology non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-701 an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML) a form of cancer that starts in bone marrow. It also develops TERN-501 a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601 a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases such as obesity. The company was incorporated in 2016 and is headquartered in Foster City California.
View LessTERN | US
Risk
37.6
Sharpe
10.81
Luna's Score
64/100
Recommendation
Hold
Luna says (TERN | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
43.6%1 month
37.6%3 months
50.3%6 months
130.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.90
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-5.80
Ent. to rev.
337.47
PEG
-
Other Fundamentals
EBITDA
-107.91M
MarketCap
3.74B
MarketCap(USD)
3.74B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-38.92
Short ratio
1.41
Short perc.
6.40
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
8.30
Range1M
10.10
Range3M
14.57
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.28
Price X volume
104.82M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.80 | 0.53 | Cheaper |
| Ent. to Revenue | 337.47 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.90 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 50.26 | 72.80 | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 3.74B | 3.66B | Par |
